SK Bioscience wins gov't order to distribute Covid-19 vaccines in S. Korea

Pulse 2021. 1. 22. 11:42
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Photo provided by SK Bioscience Co.]
SK Bioscience Co. won an order from the South Korean government to manage and operate the Covid-19 vaccine supply chain system in the country that aims to kick off nation-wide vaccinations next month.

Korea’s Public Procurement Service said Thursday it awarded SK Bioscience, a biopharmaceutical firm under SK Group, a 50.8-billion-won ($46 million) contract to set up and operate a Covid-19 vaccine logistics system.

SK Bioscience will reportedly be in charge of developing and managing a cold chain for Covid-19 vaccines, or a network of cold storage rooms and refrigerated delivery vehicles for the temperature-sensitive vaccines.

Both the company and the public agency declined to disclose the name of the vaccine that SK Bioscience will handle, while industry observers suspected the firm would be responsible for only one or two of the vaccines the country has purchased.

The Korean government so far has secured Covid-19 vaccines of a total 56 million people. Separately, it is in negotiation to secure additional doses for 20 million people from U.S drug manufacturer Novavax.

The country plans to begin Covid-19 vaccinations next month at the earliest, with Pfizer’s vaccine floated as the first batch of the government’s rollout.

SK Bioscience is a wholly owned subsidiary of SK Chemicals. It is a contract manufacturer of Covid-19 vaccines for AstraZeneca and Novavax.

On Friday, shares of SK Chemicals closed down 2.03 percent at 410,500 won, after four straight days of gains. SK Bioscience is not listed.

[ⓒ Maeil Business Newspaper &, All rights reserved]

Copyright © 매일경제 & 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?